These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
143 related items for PubMed ID: 20347366
1. Longitudinal study of body composition of 101 HIV men with lipodystrophy: dual-energy X-ray criteria for lipodystrophy evolution. Degris E, Delpierre C, Sommet A, Sire S, Lassoued S, Aquilina C, Marchou B, Massip P, Obadia M, Marion-Latard F, Bonnet E, Bernard J. J Clin Densitom; 2010; 13(2):237-44. PubMed ID: 20347366 [Abstract] [Full Text] [Related]
2. Fat mass ratio: an objective tool to define lipodystrophy in hiv-infected patients under antiretroviral therapy. Freitas P, Santos AC, Carvalho D, Pereira J, Marques R, Martinez E, Sarmento A, Medina JL. J Clin Densitom; 2010; 13(2):197-203. PubMed ID: 20347364 [Abstract] [Full Text] [Related]
3. Impact of HIV infection on total body composition in treatment-naive men evaluated by dual-energy X-ray absorptiometry comparison of 90 untreated HIV-infected men to 241 controls. Delpierre C, Bonnet E, Marion-Latard F, Aquilina C, Obadia M, Marchou B, Massip P, Perret B, Bernard J. J Clin Densitom; 2007; 10(4):376-80. PubMed ID: 17888698 [Abstract] [Full Text] [Related]
5. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population. Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J. HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291 [Abstract] [Full Text] [Related]
6. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study. McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH. Clin Infect Dis; 2005 Dec 01; 41(11):1662-70. PubMed ID: 16267741 [Abstract] [Full Text] [Related]
10. Comparison of dual-energy X-ray absorptiometry machines for measuring fat distribution changes of HIV-associated lipodystrophy. Yang Y, Zhu WD, Paton NI. Antivir Ther; 2004 Oct 01; 9(5):771-8. PubMed ID: 15535415 [Abstract] [Full Text] [Related]
12. Estimation of total-body and regional soft tissue composition from DXA bone densitometry of the lumbar spine and hip. Rosenthall L, Falutz J. J Clin Densitom; 2010 Oct 01; 13(3):263-6. PubMed ID: 20670882 [Abstract] [Full Text] [Related]
16. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study. Andersen O, Haugaard SB, Flyvbjerg A, Andersen UB, Ørskov H, Madsbad S, Nielsen JO, Iversen J. Eur J Clin Invest; 2004 Aug 01; 34(8):561-8. PubMed ID: 15305891 [Abstract] [Full Text] [Related]
18. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). Negredo E, Miró O, Rodríguez-Santiago B, Garrabou G, Estany C, Masabeu A, Force L, Barrufet P, Cucurull J, Domingo P, Alonso-Villaverde C, Bonjoch A, Morén C, Pérez-Alvarez N, Clotet B, MULTINEKA Study Group. Clin Infect Dis; 2009 Sep 15; 49(6):892-900. PubMed ID: 19663689 [Abstract] [Full Text] [Related]
19. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases]. Tao MM, Zhang L, Qiu ZF, Xie J, Han Y, Yu W, Li M, Li TS. Zhonghua Yi Xue Za Zhi; 2009 Apr 07; 89(13):867-71. PubMed ID: 19671283 [Abstract] [Full Text] [Related]